Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 11 - 20 of 35 results.

You searched for : January 2019 to January 2020.

Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at ...

Updated Phase 1 Data for Daiichi Sankyo’s U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer Download the PDF version of Article September 10, 2019...

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submissio ...

Daiichi Sankyo Advances [Fam-] Trastuzumab Deruxtecan (DS-8201) in Japan with Regulatory Submission in HER2 Positive Metastatic Breast Cancer Download the PDF version of Article September 09, 2019...

Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and ...

Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer Download the PDF version of...

Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions

Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions Download the PDF version of Article August 12, 2019 Basking Ridge, NJ – August 12, 2019 – Daiichi Sankyo, Inc....

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGC ...

FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor Download the PDF version of Article August 02, 2019 TURALIO is...

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Rela ...

Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML Download the PDF version of Article June 21, 2019 Tokyo and Basking...

Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory <i>F ...

Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML Download the PDF version of Article June 18, 2019 VANFLYTA® (quizartinib) is a FLT3...

Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with N ...

Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting Download the PDF version of Article June 02,...

Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosyno ...

Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting...

Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EG ...

Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting Download the PDF version of...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...